TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01881087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Levobupivacaine 0.75%
Description: Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Levobupivacaine 0.75%
Description: Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Levobupivacaine 0.75%
Description: Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
Study: NCT00236275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-L-thymidine-(18F)
Description: Fluoro-L-thymidine-(18F)
Study: NCT02818621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Dex (dexmedetomidine)
Description: 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group Dex (dexmedetomidine)
Description: 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
Study: NCT01420016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prioritized Clinical Decision Support
Description: Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR \>= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
Study: NCT00190372

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Controlled diet
Description: Controlled diet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-hypnotic relaxation
Description: Self-hypnotic relaxation
Study: NCT02832141

Intervention type: PROCEDURE
Intervention: Mobilization anterior
Description: Participant in prone position. Central thoracic mobilization from posterior-to-anterior.

Intervention type: PROCEDURE
Intervention: Mobilization anterior
Description: Participant in prone position. Central thoracic mobilization from posterior-to-anterior.

Intervention type: PROCEDURE
Intervention: Mobilization posterior
Description: Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.

Intervention type: PROCEDURE
Intervention: Mobilization posterior
Description: Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
Study: NCT03003000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01785849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously (IV) three times per week.
Study: NCT02248974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LVAD Decision Aid
Description: Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE).
Study: NCT02735356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Applied topically
Study: NCT03696888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecoach
Description: A skills-training web-app teaching skills for reducing problematic alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleCoach control
Description: A web-app providing information about the health-related consequences of alcohol consumption.
Study: NCT01148498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solanezumab
Description: 400mg administered once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solanezumab
Description: 400mg administered once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solanezumab
Description: 400mg administered once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solanezumab
Description: 400mg administered once intravenously
Study: NCT05333575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lullaby
Description: The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic music
Description: The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
Study: NCT03948399

Intervention type: DEVICE
Intervention: Duplex scanning of carotid arteries
Description: Measurement of carotid arteries

Intervention type: DEVICE
Intervention: Duplex scanning of carotid arteries
Description: Measurement of carotid arteries

Intervention type: DEVICE
Intervention: ABI measurement
Description: ankle brachial index (ABI) assessment

Intervention type: DEVICE
Intervention: ABI measurement
Description: ankle brachial index (ABI) assessment
Study: NCT02832284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNod System
Description: The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
Study: NCT03836742

Intervention type: PROCEDURE
Intervention: Hemofiltration with regional citrate anticoagulation
Description: To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
Study: NCT00280020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Description: Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Seminar (SS)
Description: Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
Study: NCT01013506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R inhibitor OSI-906
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R inhibitor OSI-906
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study: NCT00853229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin 150mg twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin 150mg twice daily for 4 weeks
Study: NCT02673307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 chewing gum over 45 minutes
Study: NCT03315234

Intervention type: GENETIC
Intervention: SNPs associated with CAD
Description: Genotyping will be carried out by Real-Time PCR

Intervention type: GENETIC
Intervention: SNPs associated with CAD
Description: Genotyping will be carried out by Real-Time PCR

Intervention type: GENETIC
Intervention: SNPs associated with CAD
Description: Genotyping will be carried out by Real-Time PCR
Study: NCT02192723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Typical antipsychotic
Description: Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
Study: NCT03310294

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotics and Probiotics
Description: one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
Study: NCT04324866

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
Study: NCT03357900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated titration of propofol and remifentanil
Description: Calculation of Consumption of propofol and remifentanil
Study: NCT01996657

Intervention type: DRUG
Intervention: Warfarin
Study: NCT02192723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 2\~6mg/day, twice per day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 400\~750mg/day, twice per day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine, 400～750mg/day, twice per day, 8 weeks
Study: NCT01996657

Intervention type: DRUG
Intervention: Warfarin

Intervention type: DRUG
Intervention: Warfarin
Study: NCT02519816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
Study: NCT01889355

Intervention type: DEVICE
Group type: OTHER
Intervention: AgaMatrix Blood Glucose Monitor
Study: NCT04609241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD79b CAR-T Cells
Description: Each subject receive CD79b CAR-Tcells by intravenous infusion
Study: NCT03669484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Emulsion for infusion, 10 mg/mL in 20-mL glass vials

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide
Description: Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Study: NCT02709681

Intervention type: OTHER
Intervention: Physician standard-of-care in SCD patients
Study: NCT00711607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nomegestrol acetate and estradiol
Description: Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Study: NCT02192723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole, 10～30mg/day, twice per day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Ziprasidone 80\~160mg/day, twice per day, 8 weeks
Study: NCT04255745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance training
Description: Individual, tailored, progressive muscle strength and function intervention
Study: NCT03354234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head up tilt (HUT)
Description: Model of -Gz: HUT up to 75 degrees (maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head up tilt (HUT)
Description: Model of -Gz: HUT up to 75 degrees (maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Description: Model of -Gz: LBNP down to -100 mmHg (maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Description: Model of -Gz: LBNP down to -100 mmHg (maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head down tilt (HDT)
Description: Model of +Gz: HDT down to -30 degrees (maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head down tilt (HDT)
Description: Model of +Gz: HDT down to -30 degrees (maximum)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilt table
Description: Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilt table
Description: Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LBNP chamber
Description: Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LBNP chamber
Description: Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
Study: NCT02684799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Study: NCT01584323

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomgranate pills
Description: Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
Study: NCT02714699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium
Description: patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butyl bromide
Description: patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will take oral placebo; 2 tablets one hour before the procedure
Study: NCT02877732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYE-SYNC eye-tracking
Description: The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYE-SYNC eye-tracking
Description: The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCAT-3 subtests
Description: Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCAT-3 subtests
Description: Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEM
Description: Participant will be asked to read list of numbers out loud from a card

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEM
Description: Participant will be asked to read list of numbers out loud from a card

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple Reaction Time subtest of ANAM-SRT
Description: Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Reaction Time subtest of ANAM-SRT
Description: Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level of Alertnesss
Description: Participants will answer questions. This assessment is to assess their alertness level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Level of Alertnesss
Description: Participants will answer questions. This assessment is to assess their alertness level.